Produced annually, the Cancer in North America (CiNA) statistics provide the most current cancer incidence, mortality, survival and prevalence statistics for the United States and Canada. On-line queries of current CiNA statistics visualizations and maps are available through CiNA Explorer and NAACCR maps.

CiNA OVERVIEW

NAACCR produces statistics on cancer incidence, mortality, survival and prevalence annually for the United States, Canada, and United States and Canada combined. Current CiNA statistics cover 100% of the U.S. population and 74% of the Canadian population. NAACCR has been producing CiNA statistics for over 25 years.

CiNA statistics are available at CiNA Explorer.

In 2025, cancer incidence data for cases diagnosed in 2022 for 65 of the 71 population-based cancer registries in North America were evaluated as part of the certification program—based on the December 2024 Call for Data Submission. Ten Canadian (8 Provinces and 2 territories) and 55 U.S. registries (48 states, District of Columbia, Puerto Rico, and 5 regional registries) were certified by NAACCR.

Data submitted annually to NAACCR support the creation of the CiNA statistics and other CiNA data products. For more information on CiNA data products, please visit https://www.naaccr.org/cina-data-products-overview/. Mapped cancer data are available at https://www.naaccr.org/interactive-data-on-line/.

CiNA statistics only are possible because of the continuous commitment of population-based cancer registries throughout the United States and Canada to collect timely, complete, and accurate data.

Executive Summary

For nearly 30 years, NAACCR member registries have voluntarily participated in an annual call for data submission that is used to develop a multi-registry, aggregated data resource for cancer surveillance and research. NAACCR issues and coordinates the call, and the member registries’ data submissions are combined and used to create the CiNA statistics and other CiNA products. These comprehensive cancer data resources are exceptional in geographic scope, timeliness of statistics, and assurance of standardization of information and data quality.

NAACCR first produced the flagship CiNA product—, the CiNA Monograph—, over 20 years ago as a static report covering incidence for diagnosis years 1996-2000. Since that first publication in 2003, the Monographs expanded to cover mortality, survival, and prevalence statistics. We are currently developing population attributable risk statistics.

Recently, NAACCR  have presented CiNA statistics in interactive, queriable systems in tandem with the CiNA Monograph PDFs. Production of a static document is more extensive than the on-line systems, and a review of user interaction indicated that CiNA Explorer was significantly more utilized than the traditional volumes. Based on these usage statistics, we transitioned away from the CiNA Monographs and released the CiNA statistics in CiNA Explorer exclusively in 2023.

Since then, the CiNA Editorial Workgroup has migrated CiNA statistics from the CiNA Monographs to CiNA Explorer. All critical reference materials are updated and remain accessible here, under the Data & Statistics section of the NAACCR website. The Workgroup will continue to incorporate additional statistics, such as attributable risk, into CiNA Explorer.

Historic CiNA volumes are available to download here, along with accompanying technical information and supporting appendices.

NEW THIS YEAR

1. Mortality statistics for U.S. registries are available in CiNA Explorer. Users will need to select the U.S. Combined option under Get Started with a Registry to access the mortality options.
2. Female breast cancer statistics are presented by subtype (HR+/HER2-, HR-/HER2-, HR+/HER2+, HR-/HER2+). These are available as a sub-group under the Breast, Female site group under Choose a Cancer Site.
3. Pediatric statistics are presented using the International Classification of Childhood Cancer site groupings.  These are available as a separate section, PEDIATRIC SITE RECODE (ICCC) at the end of the standard site groupings under Choose a Cancer Site.
4. Due to delays in the availability of needed denominator data, this year all CiNA statistics are age-adjusted using the standard 19 age-groups in CiNA Explorer. NAACCR plans to publish 2025 CiNA statistics using 20 age-groups, adding an 85–90 years age group.  As cancer is a significant burden among our older populations, using the additional age group provides more accurate descriptions of the burden of cancer in North America.

CiNA statistics are made possible through the continuing commitment of population-based cancer registries throughout the United States and Canada to collect timely, complete, and accurate data.

The Editors would also like to acknowledge the work and support of the National Cancer Institute, National Center for Health Statistics, National Program of Cancer Registries, and Statistics Canada for their role in producing CiNA data.

We hope that these statistics, with the companion CiNA products and resources, facilitate studies of cancer burden, so that we are better able to identify—and understand—appropriate and important measures for controlling the myriad diseases known collectively as cancer.

The CiNA Editorial WG, May 2024

DATA QUALITY ASSESSMENTS DOCUMENTATION

1. Comparison of NAACCR Data Item 190 (Spanish/Hispanic Origin) and NHIVAv2 by Registry
2. Data Quality Indicators by Year and Registry
3. Duplicate Protocol Information for the US and Canadian Registries

Technical Documentation

1. Technical Documentation — Coming Soon
2. PRCDA Counties by Indian Health Services Region and State
3. Race -Ethnic Case and Population Information for the U.S. Registries

The CiNA monograph encompasses five separate volumes:

Volume One: Combined Cancer Incidence for the United States and Canada
Includes aggregated cancer incidence data by site, sex, race, ethnicity, and stage, including pediatric cancer and cancer by stage at diagnosis from the high-quality registries in the United States and Canada.

Volume Two: Registry-Specific Cancer Incidence for the United States and Canada
Includes registry-specific cancer incidence rates by cancer site, sex, race, ethnicity, and stage for all NAACCR member registries submitting data for inclusion in the monograph. To help interpret the statistics, data tables for each registry include demographic and data quality information; registry descriptions are also presented.

Volume Three: Registry-Specific Cancer Mortality for the United States and Canada
Includes registry-specific cancer death rates by cancer site, sex, race, and ethnicity.

Volume Four: Cancer Survival for the United States and Canada
Includes cancer survival data for the United States and Canada from 59 registries on more than 13 million cases diagnosed among North Americans between 2012 and 2018.

Volume Five: Cancer Prevalence for the United States and Canada
Includes cancer prevalence estimates for the United States and Canada from 59 registries on more than 18 million cases diagnosed among North Americans between 2009 and 2018.

All CiNA volumes are available to download free of charge from the NAACCR website, along with accompanying technical data, including population data and supporting appendices. Additional visualizations of CiNA data are available as online query systems.

This publication is made possible by the continuing efforts of the NAACCR member registries. High-quality, standardized cancer incidence data aggregated across the states, provinces, territories, and regions in North America are made possible by the dedication of our members to cancer surveillance. The Editors would like to acknowledge the fine work and support of the National Cancer Institute, the National Center for Health Statistics, and Statistics Canada for their assistance in developing this publication.

We hope that Cancer in North America: 2015–2019, with the companion CiNA products and resources, facilitates studies of cancer burden, so that we are better able to identify—and understand—appropriate and important measures to control the myriad diseases known collectively as cancer.

The Editors, May 2022